Whether Sunitinib (Sutent) is a targeted drug and a detailed explanation of its mechanism of action

Sunitinib (Sunitinib) is an oral small molecule multi-target tyrosine kinase inhibitor and a typical targeted drug. It selectively inhibits a variety of receptor tyrosine kinases (RTKs), such as vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGF R), c-KIT, FLT3, RET, etc., thereby inhibiting tumor growth and angiogenesis. This targeting effect makes sunitinib broadly applicable in a variety of solid tumors and tumor types.

The main mechanism of action of sunitinib includes inhibiting tumor angiogenesis and directly inhibiting tumor cell proliferation. By inhibiting the VEGFR signaling pathway, sunitinib can block tumor angiogenesis and reduce tumor blood supply, thereby limiting tumor growth and metastasis. At the same time, inhibiting PDGFR and c-KIT can directly act on tumor cells and their microenvironment, inhibiting tumor cell proliferation and promoting apoptosis. FLT3The inhibitory effect is mainly used in the treatment of some hematological malignancies, such as acute myeloid leukemia.

In clinical applications, sunitinib has been approved for the treatment of renal clear cell carcinoma (RCC), gastrointestinal stromal tumor (GIST) and pancreatic neuroendocrine tumors (pNET). By targeting the above-mentioned receptor kinases, sunitinib can delay tumor progression and improve patients' progression-free survival (PFS) and overall survival (OS). In addition, for some patients with advanced or unresectable tumors, sunitinib provides an oral, well-tolerated long-term treatment option.

It should be noted that while it has targeted effects, sunitinib may also cause certain side effects, such as hypertension, fatigue, hand-foot syndrome, gastrointestinal discomfort, and hematological abnormalities. Therefore, when using sunitinib, patients should undergo individualized dose adjustment and regular monitoring under the guidance of a professional doctor, including blood pressure, liver and kidney function, and blood indicators, to ensure both efficacy and safety. Overall, sunitinib, as a typical targeted drug, plays an important role in tumor treatment through a multi-target inhibitory mechanism, providing an effective treatment option for patients with a variety of solid tumors.

Reference materials:https://www.drugs.com/